Physician

Jane Sperry Chawla, MD

According to 2025 Medicare claims, Jane Chawla, MD (NPI: 1487863304) practices hematology/oncology in the Austin-Round Rock-San Marcos, TX market, with the plurality of this provider's patient population coming from Travis, TX. This provider's primary affiliated billing organization is TEXAS ONCOLOGY PA (NPI: 1972770303; TIN: 752131429) and primary practice location at 78731-4214.

Chawla's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 648 traditional Medicare patients, billed 154,100 HCPCS/CPT codes, and received $2,657,893 in Medicare payments. The top billing code was 96413 (Administration of chemotherapy into vein, 1 hour or less). Part D data shows 1,164 prescription claims across 215 beneficiaries totaling $3,536,493 in drug costs, led by Revlimid (Lenalidomide). DME data shows 22 claims. Open Payments data shows 3 records totaling $121. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved from a lower plateau to a higher plateau, from $581,236 to $2,657,893. Similarly, Part D prescription costs have moved sharply higher in recent years, from $614,016 to $3,536,493. In contrast, DME billing represents a smaller volume and moved up and down with repeated peaks and valleys, starting at $3,305 and ending at $1,608.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	292	44,406	$581,236
2016	432	69,752	$1,141,651
2017	498	73,475	$1,118,996
2018	517	113,257	$1,714,591
2019	528	132,061	$1,706,055
2020	583	137,856	$1,904,282
2021	611	151,333	$2,160,294
2022	681	157,844	$2,106,115
2023	676	179,238	$2,631,237
2024	648	154,100	$2,657,893

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	95	661	$614,016
2016	101	608	$461,699
2017	125	719	$683,090
2018	138	769	$947,952
2019	142	963	$1,459,234
2020	168	1,075	$1,354,746
2021	189	1,154	$2,454,586
2022	185	1,055	$2,097,282
2023	197	1,129	$3,257,984
2024	215	1,164	$3,536,493

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	28	$770
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	N/R	22	$944
2023	N/R	24	$1,099
2024	N/R	22	$899

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
96413	Administration of chemotherapy into vein, 1 hour or less	127	332	$103
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	169	364	$92
80053	Blood test, comprehensive group of blood chemicals	199	667	$10
36415	Insertion of needle into vein for collection of blood sample	249	634	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	233	702	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Revlimid	Lenalidomide	28	746	$438,344
Brukinsa	Zanubrutinib	30	900	$437,126
Lenalidomide	Lenalidomide	29	812	$435,590
Tagrisso	Osimertinib Mesylate	26	780	$425,258
Ibrance	Palbociclib	16	448	$231,619

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
E0656	Segmental pneumatic appliance for use with pneumatic compressor, trunk	Y	N/R	11	$464
E0657	Segmental pneumatic appliance for use with pneumatic compressor, chest	Y	N/R	11	$436

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	3	$121	Incyte Corporation
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Jane Sperry Chawla, MD?

Tedicare shows public-source Medicare data for Jane Sperry Chawla, MD (NPI 1487863304), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Jane Sperry Chawla, MD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Jane Sperry Chawla, MD?

Jane Sperry Chawla, MD is linked to TEXAS ONCOLOGY PA (billing NPI 1972770303) in the available physician profile data.

Does Jane Sperry Chawla, MD have Open Payments data?

Jane Sperry Chawla, MD has 3 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.